Abstracts Archive - Page 960 of 2425 - ACR Meeting Abstracts

Abstract Number: 85 • 2019 ACR/ARP Annual Meeting
Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis Model
Tony Muchamuel¹, Janet Anderl ¹, R Andrea Fan ¹, Henry Johnson ¹, Dustin McMinn ¹ and Christopher Kirk ¹, ¹Kezar Life Sciences, South San Francisco, CA
Background/Purpose: The immunoproteasome is a distinct class of proteasome found predominantly in immune effector cells and has been shown to play a distinct role in…
Abstract Number: 86 • 2019 ACR/ARP Annual Meeting
THOR-809: An IL-2 Engineered from an Expanded Genetic Alphabet for the Potential Treatment of Autoimmune Disorders
Jerod Ptacin¹, Carolina Caffaro ¹, Lina Ma ¹, Ingrid Joseph ¹, David Chen ¹, Taylor Ismaili ¹, Kristine San Jose ¹, Yelena Pavlova ¹, Namit Singh ¹, Lilia Koriazova ¹, Hans Aerni ¹, Michael Pena ¹, Jill Mooney ¹ and Marcos Milla ¹, ¹Synthorx, La Jolla, CA
Background/Purpose: CD4+ regulatory T cells (Tregs) play a crucial role in maintaining immune homeostasis. Treg dysfunction is associated with multi-organ autoimmune (AI) and inflammatory-related diseases.…
Abstract Number: 87 • 2019 ACR/ARP Annual Meeting
KINE-101, a Novel Synthetic Peptide with Potent Regulatory T Cells Activation to Treat Rheumatoid Arthritis
Myun Soo Kim ¹, Sora Lee ¹, Jung Hyun Roh ¹, Jung A Kwon ¹, Sunyoung Park¹ and Daeho Cho ², ¹KINE SCIENCES Co. Ltd., Seoul, Republic of Korea, ²Institute of convergence science/Korea university, Seoul, Republic of Korea
Background/Purpose: Medical and patient unmet needs still existed in rheumatoid arthritis (RA) global market due to the side effects treated for long duration and sometimes…
Abstract Number: 88 • 2019 ACR/ARP Annual Meeting
Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets
Irene Cecchi¹, Massimo Radin ¹, Elena Rubini ¹, Silvia Grazietta Foddai ¹, Ana Suarez ², Elisa Menegatti ¹, Dario Roccatello ¹, Savino Sciascia ³ and Javier Rodriguez Carrio ², ¹University of Turin, Turin, Italy, ²University of Oviedo, Oviedo, Spain, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
Background/Purpose: Type I Interferons (IFN) play a key role in the pathogenesis and evolution of various autoimmune diseases. Previous studies have demonstrated that the expression…
Abstract Number: 89 • 2019 ACR/ARP Annual Meeting
Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis
Ximei Zhang¹, Julie Wang ², Nancy Olsen ³, Wael Jarjour ⁴ and Song Guo Zheng ⁴, ¹Ohio State College of Medicine, Columbus, ²Ohio State University, columbus, ³Penn State University, Hershey, PA, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Enhanced evidence supports that autoimmune diseases often result from an imbalance between regulatory T cells (Tregs) and interleukin-17-producing T helper (Th17) cells. However, under…
Abstract Number: 90 • 2019 ACR/ARP Annual Meeting
SLAMF6 Clustering Is Required to Augment Autoimmune T Cell Activation
Matthew Dragovich¹ and Adam Mor ², ¹Columbia University, New York, NY, ²Columbia University School of Medicine, New York, NY
Background/Purpose: The signaling lymphocytic activation molecule (SLAM) family is encompassed by nine distinct receptors that are hematopoietic restricted. Among these, SLAMF6 is highly expressed in…
Abstract Number: 91 • 2019 ACR/ARP Annual Meeting
Histonedeacetylase 1 (HDAC1): A Key Mediator of T Cells for the Pathogenesis of Rheumatoid Arthritis
Lisa Goschl ¹, Victoria Saferding ¹, Nicole Boucheron ², Johan Backlund ³, Alexander Platzer ¹, Kiyoshi Hirahara ⁴, Han-yu Shih ⁵, Patrick Matthias ⁶, Clemens Scheinecker ¹, Günter Steiner ⁷, Wilfried Ellmeier ² and Michael Bonelli¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Institute of Immunology, Division of Immunobiology, Medical University of Vienna, Vienna, Austria, ³Medical Inflammation Research, Karolinska Institute; Department of Medical Biochemistry and Biophysics, Stockholm, Sweden, ⁴Graduate School of Medicine, Chiba University, Chiba, Japan, ⁵National Institute of Arthritis, National Institutes of Health, Bethesda, ⁶Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland, ⁷Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria, Vienna, Austria
Background/Purpose: Despite enormous efforts to develop new therapeutic strategies for treatment of rheumatoid arthritis (RA), the large number of non responding patients to currently available…
Abstract Number: 92 • 2019 ACR/ARP Annual Meeting
Negative Immune Checkpoint Molecules on T Regulator Cells Distinguish RA, SLE and Healthy Controls
Barbara Dreo¹, Barbara Prietl ², Selina Kofler ², Harald Sourij ², Angelika Lackner ¹, Florentine Moazedi-Fuerst ¹, Monica D'Orazio ¹, Martin Stradner ¹, Winfried Graninger ¹ and Hans-Peter Brezinschek ¹, ¹Department of Internal Medicine/Division of Rheumatology and Immunology, Graz, Austria, ²2CBmed GmbH – Center for Biomarker Research in Medicine, Graz, Austria
Background/Purpose: T regulatory cells (Treg) play a crucial role in the regulation of the immune response and therefore are of utmost interest when studying autoimmune…
Abstract Number: 93 • 2019 ACR/ARP Annual Meeting
Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis
Amrutesh Puranik¹, Mark Jensen ², Regine Tipon ³, Yogita Ghodke-Puranik ³, Valeria Mezzano ⁴, Shanmugapriya Selvaraj ⁵, Theresa Wampler Muskardin ⁴, Cynthia Loomis ⁴, Ann Reed ⁶, Lauren Pachman ⁷ and Timothy Niewold ⁵, ¹NYU Langone Health, New York, NY, ²Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ³Colton Center for Autoimmunity, NYU School of Medicine, New York, ⁴New York University Langone Health, New York, ⁵New York University Langone Health, New York, NY, ⁶Duke University School of Medicine, Durham, NC, ⁷Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: T and B cells come together in ectopic lymphoid aggregates in myositis, suggesting that local T:B cell interactions could play a role in disease. …
Abstract Number: 94 • 2019 ACR/ARP Annual Meeting
Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells
Shotaro kawano¹, Hiroki Mitoma ², Shoichiro Inokuchi ³, Masahiro Ayano ², Yasutaka Kimoto ⁴, Mitsuteru Akahoshi ², Yojiro Arinobu ², Koichi Akashi ², Takahiko Horiuchi ⁵ and Hiroaki Niiro ⁶, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Japan, ³Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Fukuoka, Japan, Fukuoka, Fukuoka, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, Beppu, Japan, ⁶Clinical Education Centre, Kyushu University Hospital, Fukuoka, Japan, Fukuoka, Japan
Background/Purpose: Tumor Necrosis Factor (TNF) α is a multifunctional cytokine with pro-inflammatory and anti-inflammatory characteristics. Regulatory T cells (Treg) express a remarkably high level of…
Abstract Number: 95 • 2019 ACR/ARP Annual Meeting
IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE
Hiroshi Kato¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: IL-21 activates mechanistic target of rapamycin (mTOR) complexes 1 and 2 which in turn block regulatory T (Treg)-cell differentiation and function in patients with…
Abstract Number: 96 • 2019 ACR/ARP Annual Meeting
Characterizing the Brain T Cell Receptor Repertoire in Neuropsychiatric Lupus
Erica Moore¹, Michelle Huang ¹ and Chaim Putterman ², ¹Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, New York, NY
Background/Purpose: Approximately 40% of SLE patients experience neurological and/or psychiatric disorders, including cognitive abnormalities, mood disorders, confusion, psychosis, and seizures. However, the pathogenesis of neuropsychiatric…
Abstract Number: 97 • 2019 ACR/ARP Annual Meeting
Low Frequency of Circulating T Follicular Helper 1 Cells Is Associated to Adequate Response to Adalimumab Therapy in Rheumatoid Arthritis
Charlotte Lucas¹, Roussine Codo ², Jean-David Albert ³, Rachel Jean ², Stéphane Rodriguez ⁴, Patricia Amé-Thomas ⁵ and Aleth Perdriger ⁶, ¹Rheumatology department, Rennes University Hospital, France, Rennes, Bretagne, France, ²SITI Laboratory, Rennes University Hospital, EFS, INSERM1236, France, Rennes, Bretagne, France, ³Rheumatology department, Rennes University Hospital and Institut NUMECAN, INSERM U 1241, Rennes, Bretagne, France, ⁴PhD, SITI Laboratory, Rennes University Hospital, EFS, INSERM1236, France, Rennes, Bretagne, France, ⁵SITI Laboratory, Univ Rennes, Rennes University Hospital, EFS, INSERM1236, France, Rennes, Bretagne, France, ⁶Rheumatology department, Rennes University Hospital, France, Rennes, France
Background/Purpose: T follicular helper cells (Tfh) constitute a distinct CD4+ helper T-cell subset, promoting B-cell maturation and activation. Circulating Tfh (cTfh) seem to play a…
Abstract Number: 98 • 2019 ACR/ARP Annual Meeting
Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases
Christie Fanton¹, Neha Dixit ¹, Suresh Siddhanti ¹, Lin Lu ¹, Daniel Dickerson ², Brian Kotzin ¹ and Jonathan Zalevsky ¹, ¹Nektar Therapeutics, San Francisco, ²PRA Health Sciences, Lenexa
Background/Purpose: Regulatory T cell (Treg) dysfunction and impaired IL-2 production have been implicated as key immunological defects in multiple autoimmune diseases. Enhanced sensitivity of Tregs…
Abstract Number: 99 • 2019 ACR/ARP Annual Meeting
Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis
Runci Wang¹, Karmela Kim Chan ², Amy Cunningham-Bussel ³, Laura Donlin ⁴, Gregory Vitone ², Aidan Tirpack ², Caroline Benson ², Gregory Keras ³, Anna Helena Jonsson ⁵, Michael Brenner ⁶, Anne Bass ⁷ and Deepak Rao ¹, ¹Brigham and women's hospital, Boston, MA, ²Hospital For Special Surgery, New York, ³Brigham and women's hospital, Boston, ⁴Hospital For Special Surgery, New York, NY, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women’s Hospital:, Boston, ⁷Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Anti-PD-1/PD-L1 checkpoint inhibitor therapies have produced remarkable results in stimulating immune responses against tumors. Checkpoint inhibitor therapy can also trigger a variety of autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].